Oncotelic Therapeutics Inc.

09/24/2025 | Press release | Distributed by Public on 09/24/2025 06:47

Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Oncotelic Therapeutics Inc. published this content on September 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 24, 2025 at 12:47 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]